Israeli - Kiebrania - Ministry of Health

merck sharp & dohme israel ltd - pembrolizumab - אבקה להכנת תמיסה לאינפוזיה - pembrolizumab 50 mg/vial - pembrolizumab

Israeli - Kiebrania - Ministry of Health

astrazeneca (israel) ltd - trastuzumab deruxtecan - אבקה להכנת תמיסה מרוכזת לעירוי - trastuzumab deruxtecan 100 mg - trastuzumab

Israeli - Kiebrania - Ministry of Health

glaxo smith kline (israel) ltd - belantamab mafodotin - אבקה להכנת תמיסה מרוכזת לעירוי - belantamab mafodotin 100 mg - belantamab

Israeli - Kiebrania - Ministry of Health

bioavenir ltd, israel - fulvestrant - תמיסה להזרקה - fulvestrant 50 mg/ml - fulvestrant

Israeli - Kiebrania - Ministry of Health

pfizer pharmaceuticals israel ltd - covid-19 mrna vaccine - covid-19 mrna vaccine 0.5 mg/ml - covid-19 vaccines

Israeli - Kiebrania - Ministry of Health

astrazeneca (israel) ltd - gefitinib - טבליות מצופות פילם - gefitinib 250 mg - gefitinib - gefitinib - iressa is indicated as monotherapy for the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of both platinum-based and docetaxel chemotherapies who are benefiting or have benefited from iressa. results from two large controlled randomized trials in first-line treatment of non-small cell lung cancer showed no benefit from adding iressa to doublet platinum-based chemotherapy.iressa is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating mutations of egfr-tk.

Israeli - Kiebrania - Ministry of Health

astra zeneca (israel) ltd - bicalutamide - טבליה - bicalutamide 150 mg - bicalutamide - bicalutamide - in patients with locally advanced prostate cancer (t3 - t4 any n m0 t1 -t2 n+ m0) casodex 150 mg is indicated as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy. the management of patients with locally advanced non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable.

Israeli - Kiebrania - Ministry of Health

teva israel ltd - bicalutamide - טבליה - bicalutamide 150 mg - bicalutamide - bicalutamide - in patients with locally advanced prostate cancer (t3-t4 any n m0 t1-t2 n+ m0) bicalutamide is indicated as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy. the management of patients with locally advanced non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable.

Israeli - Kiebrania - Ministry of Health

taro international ltd - bicalutamide 150 mg - film coated tablets - bicalutamide - in patients with locally advanced prostate cancer (t3 - t4 any n m0 t1 -t2 n+ m0) bicamide 150 mg is indicated as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy. the management of patients with locally advanced non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable.

Israeli - Kiebrania - Ministry of Health

inovamed ltd - bicalutamide - טבליות מצופות פילם - bicalutamide 150 mg - bicalutamide - bicalutamide - in patients with locally advanced prostate cancer (t3 - t4 any n m0 t1 -t2 n+ m0), bicalutamide 150 mg is indicated as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy. the management of patients with locally advanced non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable